Insight Molecular Diagnostics Inc.
As of Oct 22, 2026, Insight Molecular Diagnostics is in Stage 4, the downtrend phase, now in week 12 (since Aug 3, 2026). It closed at $2.84, 66.5% below its 52-week high and below its 200-day average, which is falling.
Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally. More about the company
Pro read
ProOur read
Setup score
Momentum
Edge
Is IMDX early, or has it already run? Pro answers that for every US stock we cover, after every close.
Renews monthly until you cancel. Cancel any time in Plan & billing.
IMDX among Diagnostics & Research39th of 44 by relative strength
All 44 →| # | Stock | Stage | RS | 1M |
|---|---|---|---|---|
| 1 | CDNA | Stage 2 · wk 24 | 99 | +27.3% |
| 2 | BDSX | Stage 2 · wk 18 | 98 | −18.3% |
| 3 | ILMN | Stage 2 · wk 24 | 97 | +5.5% |
| 4 | GH | Stage 2 · wk 21 | 97 | −7.6% |
| 5 | NTRA | Stage 2 · wk 20 | 96 | +2.7% |
| 6 | CRL | Stage 2 · wk 16 | 92 | +22.5% |
| 7 | RVTY | Stage 2 · wk 18 | 90 | +10.7% |
| 8 | PSNL | Stage 2 · wk 17 | 90 | −3.2% |
| …39 | IMDX | Stage 4 · wk 12 | 20 | −27.4% |
Insight Molecular Diagnostics: quick answers
What stage is Insight Molecular Diagnostics in?
As of Oct 22, 2026, Insight Molecular Diagnostics (IMDX) is in Stage 4, the downtrend phase. It entered Stage 4 on Aug 3, 2026 and is in week 12. What the four stages mean
Is Insight Molecular Diagnostics in an uptrend?
No. Insight Molecular Diagnostics is in a Stage 4 downtrend. It trades 41.6% below its 200-day average, which is falling.
How far is Insight Molecular Diagnostics from its 52-week high?
Insight Molecular Diagnostics closed at $2.84 on Oct 22, 2026, 66.5% below its 52-week high of $8.48. Its 52-week low is $2.55.
How has Insight Molecular Diagnostics performed over the past year?
As of Oct 22, 2026, Insight Molecular Diagnostics is down 57.2% over the past year and down 60.3% so far in 2026.
Which sector and industry is Insight Molecular Diagnostics in?
Insight Molecular Diagnostics is in the Diagnostics & Research industry, part of the Health Care sector.
About this companyHealth Care· Diagnostics & Research
Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. The company also offers GraftAssureCore test, a blood test designed to measure dd-cfDNA using a novel PCR-based measurement platform, for potential patient registrants; GraftAssureIQ, a transplant monitoring assay to measure the donor-derived cell-free DNA; and GraftAssureDx, a decentralized transplant monitoring levels of donor-derived cell-free DNA in plasma following kidney transplantation to aid in the assessment of the probability of allograft rejection at the time of testing in conjunction with standard clinical assessments. In addition, it provides testing services for biomarker discovery, assay design and development, clinical trial support, and various biomarker tests. The company has a collaboration agreement with Bio-Rad Laboratories, Inc. for the development and commercialization of research use only and in vitro diagnostics kitted transplant products using Bio-Rad's ddPCR instruments and reagents. The company was formerly known as OncoCyte Corporation and changed its name to Insight Molecular Diagnostics Inc. in June 2025. Insight Molecular Diagnostics Inc. was incorporated in 2009 and is based in Nashville, Tennessee.
Visit company website →All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.